Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LENALIDOMIDE Cause Hepatic function abnormal? 238 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 238 reports of Hepatic function abnormal have been filed in association with LENALIDOMIDE (LENALIDOMIDE). This represents 0.1% of all adverse event reports for LENALIDOMIDE.

238
Reports of Hepatic function abnormal with LENALIDOMIDE
0.1%
of all LENALIDOMIDE reports
42
Deaths
102
Hospitalizations

How Dangerous Is Hepatic function abnormal From LENALIDOMIDE?

Of the 238 reports, 42 (17.6%) resulted in death, 102 (42.9%) required hospitalization, and 20 (8.4%) were considered life-threatening.

Is Hepatic function abnormal Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for LENALIDOMIDE. However, 238 reports have been filed with the FAERS database.

What Other Side Effects Does LENALIDOMIDE Cause?

Diarrhoea (27,576) Fatigue (22,956) Death (19,213) Off label use (17,017) Rash (15,794) Pneumonia (14,807) Plasma cell myeloma (14,191) Neuropathy peripheral (10,215) White blood cell count decreased (9,996) Constipation (9,635)

What Other Drugs Cause Hepatic function abnormal?

NIVOLUMAB (1,131) PEMBROLIZUMAB (1,079) METHOTREXATE (1,054) CABOZANTINIB S-MALATE (912) CYCLOPHOSPHAMIDE (824) BEVACIZUMAB (769) PACLITAXEL (603) LENVATINIB (528) ATORVASTATIN (520) CYCLOSPORINE (508)

Which LENALIDOMIDE Alternatives Have Lower Hepatic function abnormal Risk?

LENALIDOMIDE vs LENIOLISIB LENALIDOMIDE vs LENOGRASTIM LENALIDOMIDE vs LENVATINIB LENALIDOMIDE vs LEPONEX LENALIDOMIDE vs LERCANIDIPINE

Related Pages

LENALIDOMIDE Full Profile All Hepatic function abnormal Reports All Drugs Causing Hepatic function abnormal LENALIDOMIDE Demographics